Entero Historical Income Statement

ENTO Stock   0.47  0.01  2.17%   
Historical analysis of Entero Therapeutics, income statement accounts such as Depreciation And Amortization of 27.8 K or Interest Expense of 21.3 K can show how well Entero Therapeutics, performed in making a profits. Evaluating Entero Therapeutics, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Entero Therapeutics,'s future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Entero Therapeutics, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Entero Therapeutics, is a good buy for the upcoming year.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.

About Entero Income Statement Analysis

Entero Therapeutics, Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Entero Therapeutics, shareholders. The income statement also shows Entero investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Entero Therapeutics, Income Statement Chart

At this time, Entero Therapeutics,'s Interest Income is very stable compared to the past year. As of the 1st of December 2024, Selling General Administrative is likely to grow to about 13.3 M, while Net Interest Income is likely to drop (20.9 K).

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Entero Therapeutics,. It is also known as Entero Therapeutics, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Entero Therapeutics, income statement and represents the costs associated with goods and services Entero Therapeutics, provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most accounts from Entero Therapeutics,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Entero Therapeutics, current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.At this time, Entero Therapeutics,'s Interest Income is very stable compared to the past year. As of the 1st of December 2024, Selling General Administrative is likely to grow to about 13.3 M, while Net Interest Income is likely to drop (20.9 K).
 2021 2022 2023 2024 (projected)
Depreciation And Amortization542.3K29.3K29.3K27.8K
Interest Income1.2K8.4K2.5K3.5K

Entero Therapeutics, income statement Correlations

0.73-0.84-1.00.880.850.020.020.280.02-0.360.0-0.850.02-0.840.280.980.28-0.53
0.73-0.83-0.730.480.78-0.440.450.60.43-0.690.41-0.78-0.44-0.830.60.660.6-0.72
-0.84-0.830.84-0.5-1.00.51-0.55-0.75-0.550.8-0.541.00.511.0-0.75-0.89-0.750.9
-1.0-0.730.84-0.88-0.85-0.02-0.02-0.28-0.020.360.00.85-0.020.84-0.28-0.98-0.280.53
0.880.48-0.5-0.880.510.48-0.43-0.19-0.430.09-0.45-0.510.48-0.5-0.190.81-0.19-0.08
0.850.78-1.0-0.850.51-0.480.530.740.54-0.790.52-1.0-0.48-1.00.740.90.74-0.89
0.02-0.440.51-0.020.48-0.48-0.99-0.94-0.990.91-0.990.481.00.51-0.94-0.06-0.940.82
0.020.45-0.55-0.02-0.430.53-0.990.961.0-0.941.0-0.53-0.99-0.550.960.110.96-0.86
0.280.6-0.75-0.28-0.190.74-0.940.960.97-0.990.96-0.74-0.94-0.751.00.371.0-0.96
0.020.43-0.55-0.02-0.430.54-0.991.00.97-0.941.0-0.54-0.99-0.550.970.120.97-0.86
-0.36-0.690.80.360.09-0.790.91-0.94-0.99-0.94-0.930.780.910.8-0.99-0.44-0.990.98
0.00.41-0.540.0-0.450.52-0.991.00.961.0-0.93-0.52-0.99-0.540.960.110.96-0.85
-0.85-0.781.00.85-0.51-1.00.48-0.53-0.74-0.540.78-0.520.481.0-0.74-0.9-0.740.89
0.02-0.440.51-0.020.48-0.481.0-0.99-0.94-0.990.91-0.990.480.51-0.94-0.06-0.940.82
-0.84-0.831.00.84-0.5-1.00.51-0.55-0.75-0.550.8-0.541.00.51-0.75-0.89-0.750.9
0.280.6-0.75-0.28-0.190.74-0.940.961.00.97-0.990.96-0.74-0.94-0.750.371.0-0.96
0.980.66-0.89-0.980.810.9-0.060.110.370.12-0.440.11-0.9-0.06-0.890.370.37-0.61
0.280.6-0.75-0.28-0.190.74-0.940.961.00.97-0.990.96-0.74-0.94-0.751.00.37-0.96
-0.53-0.720.90.53-0.08-0.890.82-0.86-0.96-0.860.98-0.850.890.820.9-0.96-0.61-0.96
Click cells to compare fundamentals

Entero Therapeutics, Account Relationship Matchups

Pair Trading with Entero Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving together with Entero Stock

  0.7EWTX Edgewise TherapeuticsPairCorr

Moving against Entero Stock

  0.64ELAN Elanco Animal HealthPairCorr
  0.62HLN Haleon plcPairCorr
  0.59MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.5ZTS Zoetis IncPairCorr
  0.43LTRN Lantern PharmaPairCorr
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Entero Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entero Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entero Therapeutics, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entero Therapeutics, Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.04)
Return On Assets
(0.27)
Return On Equity
(0.15)
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.